FindTrial
Sign In

THOR-707

DRUG5 trials

Sponsors

Synthorx, Inc, a Sanofi company, Sanofi

Conditions

Classic Hodgkin LymphomaColorectal CancerDiffuse Large B-cell LymphomaGastric CancerHepatocellular CarcinomaMalignant MelanomaMetastasisNon-small Cell Lung Cancer

Phase 1

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)
TerminatedNCT04009681
Synthorx, Inc, a Sanofi companyMetastasis
Start: 2019-06-20End: 2025-12-02Updated: 2025-12-15
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
TerminatedNCT04913220
SanofiMalignant Melanoma, Squamous Cell Carcinoma of Skin
Start: 2021-07-15End: 2025-02-18Updated: 2026-02-04

Phase 2

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
TerminatedNCT04914897
SanofiNon-small Cell Lung Cancer, Pleural Mesothelioma
Start: 2021-09-23End: 2024-10-17Updated: 2025-10-02
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
CompletedNCT05104567
SanofiColorectal Cancer, Gastric Cancer, Hepatocellular Carcinoma +2
Start: 2021-12-09End: 2024-09-09Updated: 2025-09-24
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
TerminatedNCT05179603
SanofiClassic Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma
Start: 2021-12-07End: 2024-09-06Updated: 2025-12-24

Related Papers

Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 study.
2026-06-22
Phase 1/2 study of pegenzileukin, a pegylated recombinant non-alpha IL-2, with cemiplimab for the treatment of advanced unresectable or metastatic skin cancers.
2026-05-22
Abstract 2155: Joint modeling of safety and peripheral mode-of-action (MoA) biomarkers to support RP2D identification in Phase 1 study of SAR444245 (SAR’245) as monotherapy (mono) or combined with pembrolizumab (pembro) in patients with advanced solid tumors
Cancer Research2023-04-041 citations
481 Phase 1/2 study of THOR-707 (SAR444245), a pegylated recombinant non-alpha IL-2, as monotherapy and in combination with pembrolizumab or cetuximab in patients (pts) with advanced solid tumors
Regular and Young Investigator Award Abstracts2021-11-0113 citations
551 Pegasus Skin, a study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL2) with cemiplimab for the treatment of participants with advanced unresectable or metastatic skin cancers
Regular and Young Investigator Award Abstracts2021-11-011 citations
455 Pegasus Lung, a platform study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL-2) with anti-cancer agents in patients with non-small cell lung cancer (NSCLC) and mesothelioma
Regular and Young Investigator Award Abstracts2021-11-01
Abstract LB041: THOR-707 (SAR444245), a novel not-alpha IL-2 as monotherapy and in combination with pembrolizumab in advanced/metastatic solid tumors: Interim results from HAMMER, an open-label, multicenter phase 1/2 Study
Cancer Research2021-07-0123 citations